Whitehawk Therapeutics

Business Services · New Jersey, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

2 Headquarters Plz Bldg 11TH Fl 11, Morr...

Phone Number

(551) 321-2234

Website

www.whitehawktx.com

Revenue

Stock Symbol

WHWK

Industry

Business Services

Research & Development

ZI Rank: 1

Signal Type

Mar

Apr

May

Jun

Jul

Aug

ZI Rank

About Whitehawk Therapeutics

Whitehawk Therapeutics is an antibody drug conjugate (ADC)-focused oncology therapeutics company that employs an agile and pragmatic strategy to drug development. We start with established tumor biology targets and match them with advanced technologies to develop improved therapies for high-potential cancer indications with significant patient opportunities. By employing forward-looking trial designs, we aim to swiftly demonstrate value.Explore more

Is this data correct?

View contact profiles from Whitehawk Therapeutics

Popular SearchesWhitehawk Therapeutics IncSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: WHWKShow more

Whitehawk Therapeutics Org Chart

Phone

Bryan Ball

Chief Technical Operations Officer

Phone

Stephen Rodin

Senior VP & General Counsel

Phone

Margaret Dugan

Chief Medical Officer

Phone

Laura McLaughlin

Chief People Officer

Phone

Get the full picture

Kathleen Keegan

Vice President, Research & Development

Phone

Get the full picture

Is Whitehawk Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Congratulate Masked Content for being promoted to Masked Content at Whitehawk Therapeutics

Website visits: Recent activity has been detected on your website

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Product Launch: Get notified when Whitehawk Therapeutics launches new products

Check if Whitehawk Therapeutics has recently received funding, and reach out quickly before it becomes old news!

Check out if Whitehawk Therapeutics is spiking on competitors!

Earning: See what the market has to say on Whitehawk Therapeutics recently announced quarterly report

Whitehawk Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic

Click to see if Whitehawk Therapeutics had a recent Job posting/layoffs

Funding: Get notified immidiatlly once Whitehawk Therapeutics has new funding data

Recommended Actions

Introduce yourself to Masked Content, who has shown a strong intent to purchase lately

Find more new buyers

View Email Formats for Whitehawk Therapeutics

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Whitehawk Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Whitehawk Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Whitehawk Therapeutics.

Whitehawk Therapeutics financials insights

Gather financial insights about Whitehawk Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2026

Stock/Share Issuance

$87.5M

See All Whitehawk Therapeutics's Financials Insights

Most Recent Scoops

Person-Based

Scott Giacobello sold 141,600 shares for $584,808 on April 16th to cover tax obligations.

Stake & Stock Ownership, Finance, Tax

Project

Whitehawk Therapeutics has engineered HWK-007 with a multi-layered differentiation strategy, incorporating a high-affinity, strongly internalizing anti-PTK7 antibody with an attenuated Fc region to limit inflammatory cell uptake and reduce ILD risk, Carbon Bridge Cysteine Re-pairing conjugation chemistry for best-in-class ADC stability, PEG-based masking to extend ADC half-life, a proprietary triple alanine-based cleavage system releasing a less heme-toxic exatecan analog, and a DAR6 configuration, with trials currently clearing doses at 2 and 4 mg/kg and potential to dose up to 8 to 12 mg/kg in humans.

Pharmaceuticals

Project

presented preclinical data at AACR demonstrating a highest non-severely toxic dose (HNSTD) of 60 mg/kg across all three ADCs on its platform, a level considered relatively high within the ADC field, supporting confidence in the platform's potential therapeutic index and tolerability profile.

Pharmaceuticals

Project

Whitehawk Therapeutics is advancing HWK-007, a PTK7-directed ADC, in Phase I across non-small cell lung cancer, ovarian cancer, and endometrial cancer indications, with a 2 mg/kg cohort already enrolled and a 4 mg/kg cohort currently enrolling. The program targets an efficacy bar of approximately 40% overall response rate (ORR) in lung cancer and approximately 50% ORR in gynecological cancers, with tolerability expectations including heme-sparing effects and relatively low rates of grade 3 adverse events.

Funding

See more scoops

Top Business Services Companies

Frequently Asked Questions Regarding Whitehawk Therapeutics

What is Whitehawk Therapeutics's stock symbol?

Whitehawk Therapeutics's stock symbol is WHWK

What is Whitehawk Therapeutics's official website?

Whitehawk Therapeutics's official website is www.whitehawktx.com

What is Whitehawk Therapeutics's SIC code?

Whitehawk Therapeutics's SIC: 28,283

What is Whitehawk Therapeutics's NAICS code?

Whitehawk Therapeutics's NAICS: 32,325

How many employees does Whitehawk Therapeutics have?

Whitehawk Therapeutics has 11-50 employees

What industry does Whitehawk Therapeutics belong to?

Whitehawk Therapeutics is in the industry of: Business Services, Research & Development

How do I contact Whitehawk Therapeutics?

Whitehawk Therapeutics contact info: Phone number: (551) 321-2234 Website: www.whitehawktx.com

What does Whitehawk Therapeutics do?

What are Whitehawk Therapeutics social media links?

Whitehawk Therapeutics Linkedin page

Who invested in Whitehawk Therapeutics?

Whitehawk Therapeutics has 6 investors including Avoro Capital, Coastlands Capital, StemPoint Capital and Invus.

Is Whitehawk Therapeutics a public company?

Yes, Whitehawk Therapeutics is a public company and is traded under the symbol WHWK

See more information about Whitehawk Therapeutics

Whitehawk Therapeutics Latest Hires and Their Positions

Whitehawk Therapeutics is expanding and recently hired new employees. Here are the latest additions to the team.

Joe Fitzgerald

Vice President, Clinical Data & Evidence

Joined Feb 1, 2026

Phone

Margaret Dugan

Chief Medical Officer

Joined Dec 1, 2025

Phone

Jennifer Magallanes

Manager, Accounting

Joined Sep 1, 2025

Phone

Sell Smarter. Win Faster.

Level up your game to ZoomInfo Copilot, intuitive AI that turns your data and high-quality ZoomInfo data into an unfair advantage for your go-to-market teams.